Thrombocytopenia clinical trials

The registry lists 482 studies for Thrombocytopenia across more than 10 countries. 100 are recruiting or about to start. 251 of them are mainly about Thrombocytopenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 6 narrower conditions too, such as Purpura, Thrombocytopenic, Idiopathic: 1,092 studies, 295 open.

Get an email when these change. Save the Thrombocytopenia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 233
Recruiting: 66
Status unknown: 60
Terminated: 58
Not yet recruiting: 30
Withdrawn: 19

Phase

Phase 2: 178
Phase 3: 85
Phase 1: 55
Phase 4: 32
Early Phase 1: 8

Where

United States: 176
China: 108
France: 58
Italy: 39
Canada: 34
Germany: 33

Who runs them

GlaxoSmithKline (21) · Amgen (20) · National Heart, Lung, and Blood Institute (NHLBI) (14) · Institute of Hematology & Blood Diseases Hospital, China (10) · Shandong University (10) · M.D. Anderson Cancer Center (10) · Novartis Pharmaceuticals (7) · Peking University People's Hospital (7)

What is being tested here

Drugs under test in Thrombocytopenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Hetrombopag	7	1	8
Avatrombopag	5	6	22
Romiplostim	3	9	33
Recombinant human thrombopoietin	3	5	14
Telitacicept	2	0	2
Selinexor	2	0	2
Tretinoin	2	0	2
Hetrombopag olamine	2	0	2
Eltrombopag	1	13	52
Cyclosporine	1	0	6

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 1 open · Calcineurin inhibitors 1 open · Antifibrinolytics 1 open · Corticosteroids 1 open

Coming up

15phase 3 studies under way

26studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Apr 2027QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia · Phase 3 · Qilu Pharmaceutical Co., Ltd.
Sep 2027Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study · Phase 3 · Zhongda Hospital
Oct 2027Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · First Affiliated Hospital of Zhejiang University
Nov 2026Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms · Fondazione Italiana Sindromi Mielodisplastiche-ETS
Dec 2026STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis · Tzu-Fei Wang
Dec 2026Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia · Methodist Health System
Dec 2026Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation · Anhui Provincial Hospital
Jan 2027Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia · Anhui Provincial Hospital
Feb 2027Luspatercept for Clonal Cytopenias of Uncertain Significance · Weill Medical College of Cornell University
Apr 2027Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia · University of Manitoba

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger. 10 (15%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 3 (5%) take healthy volunteers.

Recruiting studies that take each age, of 66
Age	Women	Men
10	5 (8%)	5 (8%)
18	63 (95%)	62 (94%)
30	62 (94%)	61 (92%)
40	62 (94%)	61 (92%)
50	62 (94%)	61 (92%)
65	59 (89%)	58 (88%)
75	54 (82%)	53 (80%)
85	48 (73%)	47 (71%)

Across all 482 studies, recruiting or not: 28% stop at 75 or younger and 16% at 65; 23% take children; 4% are for women only and 1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thrombocytopenia studies take

Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	15 mo6–36 · 18 studies	—	—
Phase 2	36 mo28–81 · 54 studies	—	63 mo33–83 · 44 studies
Phase 3	34 mo22–45 · 29 studies	—	—
Interventional, no phase	20 mo11–44 · 25 studies	—	—
Observational	32 mo20–56 · 41 studies	—	27 mo13–63 · 36 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting4

Newly registered6

Show 1 more

Neonatal Thrombocytopenia in the NICUOct 20, 2026NCT07882342

Studies

Recruiting first, then most recently updated. Showing 50 of 482. Browse all 482 → or search them.